WNT Pathway Gene Mutations Are Associated With the Presence of Dysplasia in Colorectal Sessile Serrated Adenoma/Polyps

American Journal of Surgical Pathology

Volumn 41, Issue 9, 2017, Pages 1188-1197

  Hashimoto, Taiki ^a,b   Yamashita, Satoshi ^c   Yoshida, Hiroshi ^a   Taniguchi, Hirokazu ^a   Ushijima, Toshikazu ^c   Yamada, Tesshi ^b,c   Saito, Yutaka ^a   Ochiai, Atsushi ^d   Sekine, Shigeki ^a,c   Hiraoka, Nobuyoshi ^a,c  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d NATIONAL CANCER CENTER   (Japan)

Author keywords

dysplasia; RNF43; sessile serrated adenoma polyp; WNT

Indexed keywords

ADENOMA; ADULT; AGED; COLORECTAL TUMOR; FEMALE; GENETICS; HUMAN; INTESTINE POLYP; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; VERY ELDERLY; WNT SIGNALING;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INTESTINAL POLYPS; MALE; MIDDLE AGED; MUTATION; WNT SIGNALING PATHWAY;

EID: 85020709460     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000877     Document Type: Article

References (56)

1. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50:113-130.
2. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010;138:2088-2100.
3. Bettington M, Walker N, Clouston A, et al. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology. 2013;62:367-386.
4. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525-532.
5. Rajagopalan H, Nowak MA, Vogelstein B, et al. The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer. 2003;3:695-701.
6. Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol. 2011;42:1-10.
7. O'Brien MJ, Zhao Q, Yang S. Colorectal serrated pathway cancers and precursors. Histopathology. 2015;66:49-65.
8. Dehari R. Infrequent APC mutations in serrated adenoma. Tohoku J Exp Med. 2001;193:181-186.
9. Sawyer EJ, Cerar A, Hanby AM, et al. Molecular characteristics of serrated adenomas of the colorectum. Gut. 2002;51:200-206.
10. Yamamoto T, Konishi K, Yamochi T, et al. No major tumorigenic role for beta-catenin in serrated as opposed to conventional colorectal adenomas. Br J Cancer. 2003;89:152-157.
11. Yang S, Farraye FA, Mack C, et al. BRAF and KRAS mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am J Surg Pathol. 2004;28:1452-1459.
12. Kambara T, Simms LA, Whitehall VL, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut. 2004;53:1137-1144.
13. O'Brien MJ, Yang S, Mack C, et al. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol. 2006;30:1491-1501.
14. Kakar S, Deng G, Cun L, et al. CpG island methylation is frequently present in tubulovillous and villous adenomas and correlates with size, site, and villous component. Hum Pathol. 2008;39:30-36.
15. Sekine S, Yamashita S, Tanabe T, et al. Frequent PTPRK-RSPO3 fusions and RNF43 mutations in colorectal traditional serrated adenoma. J Pathol. 2016;239:133-138.
16. Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012;18:890-900.
17. Lochhead P, Kuchiba A, Imamura Y, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013;105:1151-1156.
18. Seppälä TT, Böhm JP, Friman M, et al. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br J Cancer. 2015;112:1966-1975.
19. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005;65:6063-6069.
20. Pai RK, Jayachandran P, Koong AC, et al. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol. 2012;36:744-752.
21. Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015;148:77-87. e2.
22. Spring KJ, Zhao ZZ, Karamatic R, et al. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology. 2006;131:1400-1407.
23. Torlakovic E, Skovlund E, Snover DC, et al. Morphologic reappraisal of serrated colorectal polyps. Am J Surg Pathol. 2003;27:65-81.
24. Sheridan TB, Fenton H, Lewin MR, et al. Sessile serrated adenomas with low- and high-grade dysplasia and early carcinomas: an immunohistochemical study of serrated lesions "caught in the act". Am J Clin Pathol. 2006;126:564-571.
25. Goldstein NS. Small colonic microsatellite unstable adenocarcinomas and high-grade epithelial dysplasias in sessile serrated adenoma polypectomy specimens: a study of eight cases. Am J Clin Pathol. 2006;125:132-145.
26. Rosty C, Hewett DG, Brown IS, et al. Serrated polyps of the large intestine: current understanding of diagnosis, pathogenesis, and clinical management. J Gastroenterol. 2013;48:287-302.
27. Yang HM, Mitchell JM, Sepulveda JL, et al. Molecular and histologic considerations in the assessment of serrated polyps. Arch Pathol Lab Med. 2015;139:730-741.
28. Yachida S, Mudali S, Martin SA, et al. Beta-catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. Am J Surg Pathol. 2009;33:1823-1832.
29. Fujita K, Yamamoto H, Matsumoto T, et al. Sessile serrated adenoma with early neoplastic progression: a clinicopathologic and molecular study. Am J Surg Pathol. 2011;35:295-304.
30. Dhir M, Yachida S, Van Neste L, et al. Sessile serrated adenomas and classical adenomas: an epigenetic perspective on premalignant neoplastic lesions of the gastrointestinal tract. Int J Cancer. 2011;129:1889-1898.
31. Murakami T, Mitomi H, Saito T, et al. Distinct WNT/beta-catenin signaling activation in the serrated neoplasia pathway and the adenoma-carcinoma sequence of the colorectum. Mod Pathol. 2015;28:146-158.
32. Bettington M, Walker N, Rosty C, et al. Clinicopathological and molecular features of sessile serrated adenomas with dysplasia or carcinoma. Gut. 2017;66:97-106.
33. Tsai JH, Liau JY, Yuan CT, et al. RNF43 is an early and specific mutated gene in the serrated pathway, with increased frequency in traditional serrated adenoma and its associated malignancy. Am J Surg Pathol. 2016;40:1352-1359.
34. Yan HH, Lai JC, Ho SL, et al. RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation. Gut. 2016. [Epub ahead of print].
35. Koo BK, Spit M, Jordens I, et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature. 2012;488:665-669.
36. Furukawa T, Kuboki Y, Tanji E, et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep. 2011;1:161.
37. Wu J, Jiao Y, Dal Molin M, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A. 2011;108:21188-21193.
38. Ong CK, Subimerb C, Pairojkul C, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012;44:690-693.
39. Jiang X, Hao HX, Growney JD, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A. 2013;110:12649-12654.
40. Ryland GL, Hunter SM, Doyle MA, et al. RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary. J Pathol. 2013;229:469-476.
41. Wang K, Yuen ST, Xu J, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014;46:573-582.
42. Giannakis M, Hodis E, Jasmine Mu X, et al. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet. 2014;46:1264-1266.
43. Bond CE, McKeone DM, Kalimutho M, et al. RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis. Oncotarget. 2016;7:70589-70600.
44. Bettington ML, Walker NI, Rosty C, et al. A clinicopathological and molecular analysis of 200 traditional serrated adenomas. Mod Pathol. 2015;28:414-427.
45. Snover DC, Ahnen DJ, Burt RW, et al. Serrated polyps of the colon and rectum and serrated polyposis. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumours of the Digestive System, 4th ed. Lyon, France: IARC; 2010:160-165.
46. Baker AM, Van Noorden S, Rodriguez-Justo M, et al. Distribution of the c-MYC gene product in colorectal neoplasia. Histopathology. 2016;69:222-229.
47. Bettington M, Walker N, Rosty C, et al. Critical appraisal of the diagnosis of the sessile serrated adenoma. Am J Surg Pathol. 2014;38:158-166.
48. Barker N, Ridgway RA, van Es JH, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature. 2009;457:608-611.
49. Seshagiri S, Stawiski EW, Durinck S, et al. Recurrent R-spondin fusions in colon cancer. Nature. 2012;488:660-664.
50. Oka S, Tanaka S, Hiyama T, et al. Clinicopathologic and endoscopic features of colorectal serrated adenoma: differences between polypoid and superficial types. Gastrointest Endosc. 2004;59:213-219.
51. Kim MJ, Lee EJ, Suh JP, et al. Traditional serrated adenoma of the colorectum: clinicopathologic implications and endoscopic findings of the precursor lesions. Am J Clin Pathol. 2013;140:898-911.
52. Bettington ML, Chetty R. Traditional serrated adenoma: an update. Hum Pathol. 2015;46:933-938.
53. Chetty R. Traditional serrated adenoma (TSA): morphological questions, queries and quandaries. J Clin Pathol. 2016;69:6-11.
54. Lee EJ, Chun SM, Kim MJ, et al. Reappraisal of hMLH1 promoter methylation and protein expression status in the serrated neoplasia pathway. Histopathology. 2016;69:198-210.
55. Kim KM, Lee EJ, Ha S, et al. Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea. Am J Surg Pathol. 2011;35:1274-1286.
56. Inoue A, Okamoto K, Fujino Y, et al. B-RAF mutation and accumulated gene methylation in aberrant crypt foci (ACF), sessile serrated adenoma/polyp (SSA/P) and cancer in SSA/P. Br J Cancer. 2015;112:403-412.